Knight Therapeutics (TSX:GUD) GF Value : C$6.78 (As of Mar. 16, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics GF Value?

As of today (2025-03-16), Knight Therapeutics's share price is C$5.99. Knight Therapeutics's GF Value is C$6.78. Therefore, Knight Therapeutics's Price-to-GF-Value for today is 0.88. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Knight Therapeutics is Modestly Undervalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Knight Therapeutics (TSX:GUD) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Knight Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	5.99	/	6.78
	=	0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Executives

Sime Armoyan	10% Security Holder
Samira Sakhia	Director, Senior Officer
Amal Khouri	Senior Officer
Jonathan Ross Goodman	Director, Director or Senior Officer of 10% Security Holder
Robert Nathaniel Lande	Director
Janice Jean Murray	Director
Nicolas Sujoy	Director
Long Zone Holdings Inc.	10% Security Holder
Arvind Utchanah	Senior Officer
Michael Joseph Tremblay	Director
James Gale	Director
Michael Dehn	Director, Senior Officer
Andrew Moor	Senior Officer
Patrick Mcclymont	Senior Officer
Kevin Drew Nabholz	Director

Knight Therapeutics Headlines

No Headlines